Whether you need the full eCOMPASS platform or targeted expertise at one stage, we will connect you with an RNA expert to scope the right engagement for your program.
Talk to an RNA expertRNA Therapeutic Development Support
Whether you need a full design-to-characterization platform or targeted expertise at one stage, Eclipsebio supports RNA therapeutic programs from early optimization through preclinical advancement. Our capabilities span AI-driven sequence design, rapid prototyping, and sequencing-based analytics, available as an integrated closed loop or as individual capabilities that plug into your existing workflow.
RNA development that fits your program
Eclipsebio supports RNA therapeutic programs at any stage. Teams can engage across eCOMPASS, our full closed loop of design, make, and characterize, to rapidly iterate and optimize candidates using integrated AI, RNA prototyping, and sequencing-based analytics. For teams with existing capabilities, we plug in where needed: design-only optimization through eNAVIGATE, nucleotide-level characterization through eMERGE, or connections with qualified manufacturing partners for scale-up. This flexible approach enables faster decisions, reduced risk, and confident progress toward the clinic.
Learn about eCOMPASSThe insights that drive confident decisions
Standard IVT RNA development approaches tell you a molecule passed or failed. The insights below tell you why, and what to do next. Each one represents a specific question we answer with nucleotide-level resolution.
Which host proteins will regulate your therapy?
After delivery, host RNA-binding proteins can interact with your therapy at specific positions, influencing stability, localization, and translational output. eNAVIGATE predicts these regulatory interactions during sequence design so you can optimize around them, not discover them after candidates are already in production.
Predicted RNA-binding protein interaction sites mapped across the nucleotide positions of an mRNA sequence. Each row represents a host protein; teal bars indicate predicted binding positions. These interactions can influence therapeutic efficacy.
Which bases and structures are generating dsRNA?
Bulk dsRNA assays tell you contamination is present but not where it comes from. Our eMERGE analytics platform reveals dsRNA to the specific nucleotide positions and structural features responsible, so your team can target the root cause in the sequence or manufacturing process rather than iterating blind.
RNA secondary structure with nucleotide positions highlighted in red where base pairing leads to dsRNA formation. Sequencing-based analytics resolve dsRNA contamination and sources to specific features, not just bulk presence.
How well is your therapy being translated?
Ribosome profiling measures the ribosome association of your transfected mRNA and compares it directly against the host transcriptome. This tells you whether your therapeutic is competing effectively for translational machinery after delivery, and identifies the specific positions where translation stalls or drops off. The result is a clear, quantitative read on translational performance that connects sequence design decisions to functional outcomes.
Distribution of ribosome occupancy across host genes (gray) compared to the transfected mRNA therapeutic (orange). The position of the therapeutic relative to the host transcriptome provides a direct, quantitative measure of translational performance after delivery.
What our
partners say
"Eclipsebio’s analysis of RNA folding has provided valuable insights necessary to understand the impact of RNA sequence and chemical modifications on secondary structures…to help improve the design of our RNAs and rationalize our internal findings."
"At Acuitas we are interested in how modifications to LNP formulations can impact efficacy and stability. Eclipsebio’s eSHAPE assay has potentially revealed direct correlations between LNP composition and RNA secondary structure, further adding to our understanding of the mechanism of action for RNA-LNP systems."